Molecular marker-aided breeding/selection cannot be considered as conventional breeding. Conventional breeding generally refers to traditional methods such as selection, hybridization, and back-crossing based on observable traits. In contrast, molecular marker-based selection involves the use of molecular tools and genetic markers to identify and select desirable traits at the DNA level, and therefore falls outside the scope of conventional breeding.
As per Section 36 of the BD Act, 2002, the Central Government (Ministry of Environment, Forest and Climate Change) shall develop national plans for the conservation, promotion and sustainable use of biological resources. The State Government shall develop state plans for the conservation, promotion and sustainable use of the biological diversity in conformity with the national strategies, plans and programmes, as per Section 36B of the amended BD Act.
In October, 2024, India’s updated national biodiversity strategy and action plan was prepared in alignment with the Kunming-Montreal Global Biodiversity Framework. India released the same in the side event of the COP-16 meeting at Cali, Colombia.
Yes, as defined under Section 2(c) of the Act, biological resources include ‘derivatives’. Section 2(fa) defines “derivative” as a naturally occurring biochemical compound or metabolism of biological resources, even if it does not contain functional units of heredity. Therefore, access to derivatives for undertaking the activities in the Act requires prior approval.
utilising the benefit-sharing amount received by the NBA?
As per Section 27(2) of the Act, the benefit sharing amount realized by the NBA shall be utilised for the following purposes:
The applicant shall be liable to pay up to 5.0% of the monetary benefit received from the transferee, as a benefit-sharing amount, as determined by the NBA on a case-by-case basis.
Yes, the BD Act, 2002 has been amended twice as given below:
The application forms for getting specific permissions are available on the ABS e-filing portal. After receiving the application complete in all aspects, the NBA will examine and verify the information. If the application is found in order, the Competent Authority shall grant necessary approval.
No. Section 5 exempts transfer or exchange of biological resources or TK associated thereto between institutions under collaborative research projects from obtaining approval for the purpose of research provided that such research projects conform to the policy guidelines issued by the Central Government from time to time. The principal investigator of the Indian institution is required to furnish the following to the NBA;
Yes, the name of the applicant and the biological resources mentioned in the IPR-related forms (Forms 6-9) must be consistent with the details provided in the corresponding patent applications. This alignment ensures that the NBA can check the information between the patent application and the IPR forms. Discrepancies in the applicant's name or the biological resources listed may result in delays or complications during the approval process. Therefore, to maintain transparency, compliance, and consistency, the details provided in both the patent application and the NBA forms should be identical.
Section 2(ea) of the Act defines “codified traditional knowledge” as the knowledge derived from authoritative books specified in the First Schedule to the Drugs and Cosmetics Act, 1940. Access to such codified traditional knowledge is exempted for Section 7 persons (individual/entity).
ln the event of developing hybrids combination of both lndian and non-lndian biological resources, the ABS will be calculated proportionate use of lndian biological resources, on a case-by-case basis. However, the scientific proof of onus lies with the applicant.
No. The activity of “video graphing” and “camera trapping” does not fall within the scope of Sections 3, 4, 6 or 20 of the Act and therefore no approval is required from the NBA.
Yes, as per the BD (Amendment) Act, 2023, access to biological resources which are occurring in or obtained from India, including those deposited in repositories outside India would attract the provisions of the Act.
As per Section 32(2) of the Act, the benefit sharing amount collected by the SBBs/UTBCs shall be utilised for the following purposes:
As per Regulation 7 of the BD (ABS) Regulations, 2025, where no budgetary allocation has been made specifically for the benefit sharing under a sponsored research project, the sponsoring organisation shall be required to provide an undertaking. This undertaking must state that, in the event the results of research are utilised for commercialisation, the resultant benefits shall be shared with the NBA. Further, any Indian person awaiting sponsorship for such projects is obligated to keep the sponsoring entity informed of this requirement.
The key objectives of the amendments introduced to the Act are as follows:
Yes. Accessing soil or water samples with the intent to analyse microorganisms are regulated under the BD Act. Prior approval of the NBA must be obtained as per Section 3 & 6 of the Act.
No. The collaborative research projects that fulfil the conditions laid down in the policy guidelines notified by the Central Government are exempted from the approval for undertaking research under Section 5 of the BD Act.
However, a proforma, along with the approval of the Government, in the format prescribed by the NBA, has to be submitted to the NBA by the Indian institution before the exchange or transfer of biological resources. While transferring the results of the research to the institute outside India, approval from the NBA has to be obtained by the Indian collaborator.
Prior approval of the NBA is mandatory before accessing the biological resource for the purpose of research or obtaining IPR. He must apply in Form-1 for research and Form-7 for obtaining IPR, as the biological resources occurring in or obtained from India are regulated under the BD Act. The application forms are available on the ABS e-filing portal.
Section 2(p) of the Act defines “value added products” as products which may contain portions or extracts of plants and animals in unrecognizable and physically inseparable form. Access to value added products is exempted from the purview of the BD Act only if the products meet the criteria given in Section 2(p) of the Act.
Version of FAQ:
Date of FAQ:
Website Content Managed by National Biodiversity Authority, Goverment of India